Exelixis | EXEL - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Akebia Therapeutics USD 155.55M 7.1M 2026-06
Amgen USD 13.99B 1.95B 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Bayer EUR 4.29B 1.44B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Cytokinetics USD 255.27M 125.43M 2026-06
Eisai JPY 245.42B 56.22B 2026-03
Eli Lilly USD 8.95B 3.67B 2026-06
Exelixis USD 281.45M 55.3M 2026-06
Genmab DKK 1.5B 18M 2026-06
Glaxosmithkline GBP 3.44B 146M 2026-03
Incyte USD 3.98B 33.45M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
MacroGenics USD 113.91M 47.39M 2026-06
Merck USD 6.85B 1.52B 2026-06
Moderna USD 1.72B 185M 2026-06
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Novartis USD 7.62B 739M 2026-06
Pfizer USD 976M 727M 2026-06
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sanofi EUR 5.54B 2.11B 2026-03
Takeda JPY 460.98B 134.07B 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Xencor USD 44.66M 30.49M 2026-06